Some labs close because they lost a major referring account or got dropped from a payer network. Those closures make sense to everyone watching, and there is usually a clear moment you can point to.
The ones I want to talk about are the other kind. The lab that was busy right up to the last month. Specimens still arriving, instruments still running, staff still working, and nothing on the schedule suggesting anything was wrong.
What ran out was cash. Not revenue. Cash.
That distinction is the whole story, and it is the part that gets noticed too late. A lab can bill more this year than it billed last year and still be closer to closing, because billing is not collecting. The gap between the two is the revenue cycle, and when that gap widens quietly, nothing in your day tells you it is happening.
I should be straight about where this comes from. I am not a lab director and I have never run a bench. What I do is bring in specialists who spend their careers inside revenue cycles, and the pattern below is what they keep finding when they look. It is remarkably consistent, and almost none of it is exotic.
Revenue you earned is not revenue you were paid
Every test you run creates a claim. Every claim goes through a process that can reduce it, delay it, or end it. Along the way, an amount you consider earned turns into a smaller amount you actually receive, and often a much later one.
The reasons are ordinary. A code that does not match the payer's current policy. A prior authorization that was needed and nobody flagged. A demographic field that came in wrong from the ordering office. A contract that reimburses at a rate nobody has checked against the fee schedule since it was signed.
None of these look like a crisis on the day they happen. Each one is a small correction on a single claim. The problem is that they repeat, on volume, every day, and the total never shows up as a line item anywhere. There is no invoice for money you never received.
Where the money actually leaks
Denials that get written off instead of worked
A denial is not a decision. It is the start of a conversation, and a meaningful share of them are reversible when they are worked correctly and on time. What kills labs is not the denial rate. It is the share of denials that quietly become write-offs because nobody had the hours to appeal them and the filing window closed.
Underpayments nobody compares against the contract
Payers do not always pay what the contract says. If nothing in your process compares the remittance to the negotiated rate, line by line, an underpayment is indistinguishable from a payment. It clears, it posts, the claim closes, and the difference is gone. This is the single most common leak we find, and it is invisible by design.
Front-end errors that become back-end losses
Most denials are created before the specimen is ever processed, at registration and order entry. Wrong plan, missing authorization, eligibility that lapsed, a subscriber ID transposed by one digit. Fixing it downstream costs many times what catching it upfront would have cost, assuming it can be fixed at all.
Aging AR that stopped being real
Every AR report has a tail. The question is whether the tail is collectible or whether it has quietly become a list of claims past their appeal window that are still counted as assets. A lab can look solvent on a balance sheet built largely out of money it will never see.
Payer contracts that were signed and never revisited
Rates get negotiated once, usually at a moment when the lab had the least leverage it would ever have. Volume grows, the case mix changes, the market moves, and the contract stays exactly where it was. Nothing forces a review. You have to go looking.
Cost per test that drifted
Reagents, send-outs, couriers, instrument service agreements, and reference lab pricing all move. If the cost side is drifting up while the reimbursement side is flat or down, the margin on a test can invert without a single alarming invoice crossing your desk.
Why this hides so well
Three things make revenue cycle erosion unusually hard to see.
It is distributed. No single claim is worth investigating. The loss only exists in aggregate, and aggregate is exactly the view nobody builds.
It looks like normal operations. Denials, appeals, and adjustments are a routine part of the work. There is no clean line between a healthy amount of friction and a failing process, so the drift never announces itself.
It is measured with the wrong number. Labs tend to watch volume and gross billing, because those are the numbers that are easy to produce. Net collection against expected reimbursement is the number that actually predicts survival, and it is harder to assemble, so it often does not get assembled at all.
By the time the pattern is undeniable, the shortfall is usually a year or more deep, and the cash to fix it is the cash that already left.
What to look at first
You do not need a full audit to find out whether you have a problem. You need five answers.
1. What percentage of your claims are denied on first submission, and what happens to those claims next? Specifically: who works them, and what share are appealed before the filing deadline?
2. Does anything in your process compare what a payer actually paid against what your contract says they owed? If the answer is no, you cannot know whether you are being underpaid.
3. How much of your AR is past the point where it can still be appealed, and is it still sitting in your reported receivables?
4. When was each payer contract last renegotiated, and what has changed about your volume or case mix since then?
5. What does a given test cost you today, all in, versus what it reimburses today? Not what it cost when you priced it.
If any of these takes more than a day to answer, that is itself the finding. A process you cannot see is a process nobody is managing.
Frequently asked questions
Is this a billing company problem?
Sometimes, but blaming the biller usually misses it. A billing company is measured on claims submitted and payments posted. Very few are structured or paid to fight underpayments or to renegotiate your contracts, because that is not what they were hired to do. The gap is often nobody's job rather than somebody's failure.
Our volume is growing. Doesn't that solve it?
Growth makes it worse, not better. Every leak in the process scales with the volume running through it, and growth also consumes cash. Labs that grow into a broken revenue cycle close faster than labs that stay flat.
How far back can underpayments be recovered?
That depends on the payer, the contract, and the timely filing and appeal provisions in each agreement. Some of it is recoverable and some of it is not, which is exactly why the comparison needs to be running continuously rather than once a year.
We are too small for this to matter.
Smaller labs are the most exposed, not the least. A large system absorbs a percentage of leakage. A small lab operating on thin margins does not have the cushion, and it usually does not have a dedicated revenue cycle analyst either.
The bottom line
Labs do not usually fail at the thing they are good at. They fail at the process that turns the work into money, and that process erodes in small enough increments that it never triggers a reaction until the cash position does.
If nobody at your lab can tell you, this week, what percentage of expected reimbursement you actually collected last quarter, that is not a reporting gap. That is the risk itself.
This is the same pattern that shows up in reducing business costs across the board: money leaves quietly, in small amounts, through a process nobody owns. Billing is simply the version where the amounts are largest.
If you would like a no-cost revenue cycle review, you can book a free consultation. If your process is already tight, there is nothing to find and nothing to pay.
